Mar 25, 2019
Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting
Mar 20, 2019
Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
Mar 19, 2019
AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program
Mar 18, 2019
Ascentage Pharma Appoints Thomas J. Knapp as Senior Vice President, General Counsel
Mar 07, 2019
AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients
Feb 14, 2019
Ascentage Pharma Appoints Jeff Kmetz as Chief Business Officer
Feb 05, 2019
Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax
Jan 08, 2019
Ascentage Pharma Announces New License with Unity Biotechnology
Jan 06, 2019
Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development
Dec 04, 2018
Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma
Dec 01, 2018
AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course
Nov 01, 2018
AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Oct 31, 2018
AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia
Oct 30, 2018
Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax
Sep 11, 2018
Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label
Jul 17, 2018
Ascentage Pharma Raises $150 Million in Series C Financing
Jul 12, 2018
AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Jun 15, 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
May 31, 2018
AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress
May 21, 2018
Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting